Drug companies lose appeal on 340B rebates
AI Briefing
- • Four drug manufacturers lose court battle on 340B rebate switch.
- • US Court of Appeals upholds lower court's ruling on rebate requirement.
- • Manufacturers must provide rebate mechanism before switching to rebates.
Context
Four drug manufacturers have lost their appeal to change the pricing mechanism for certain 340B drugs from up-front discounts to rebates. The U.S. Court of Appeals for the District of Columbia Circuit made this decision, affirming a lower court's ruling in a case involving Novartis Pharmaceuticals Corp.
The court's ruling matters because it clarifies the process for implementing rebate mechanisms for 340B prices. According to the ruling, the Department of Health and Human Services secretary must provide for a rebate mechanism before manufacturers can switch to rebates.
Advertisement